Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drugs With Abuse Potential Should Recruit Two Types Of Patients For Trials

Executive Summary

FDA is encouraging sponsors conducting clinical trials to assess the abuse potential of a new drug to enroll "drug-naive healthy subjects" as well as "experienced, recreational drug users who have a recent or current history of using a drug in the pharmaceutical class of the test drug.

You may also be interested in...



DEA Scheduling Delays Can Be Reduced With Early Studies, Frequent Sharing

Early interactions with FDA and the Drug Enforcement Administration may help drug sponsors avoid a long lag time between NDA approval and controlled substance scheduling, industry and agency experts said at the Food and Drug Law Institute’s annual meeting.

DEA Scheduling Delays Can Be Reduced With Early Studies, Frequent Sharing

Early interactions with FDA and the Drug Enforcement Administration may help drug sponsors avoid a long lag time between NDA approval and controlled substance scheduling, industry and agency experts said at the Food and Drug Law Institute’s annual meeting.

Regulatory Science: FDA Gets Help From NIH, But Is It Enough?

The Food and Drug Administration is turning to the National Institutes of Health in its quest for fresh intellectual firepower to keep its regulatory science upgrade program moving ahead. [Editor's note: This story, including the headline, has been modified to correct figures related to funding for the Critical Path initiative.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051886

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel